| Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms M Kleppe, R Koche, L Zou, P van Galen, CE Hill, L Dong, S De Groote, ... Cancer cell 33 (1), 29-43. e7, 2018 | 290 | 2018 |
| Loss of function of GALNT2 lowers high-density lipoproteins in humans, nonhuman primates, and rodents SA Khetarpal, KT Schjoldager, C Christoffersen, A Raghavan, ... Cell metabolism 24 (2), 234-245, 2016 | 125 | 2016 |
| A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels SA Khetarpal, X Zeng, JS Millar, C Vitali, AVH Somasundara, P Zanoni, ... Nature medicine 23 (9), 1086-1094, 2017 | 122 | 2017 |
| The molecular basis of mammary gland development and epithelial differentiation PF Slepicka, AVH Somasundara, CO Dos Santos Seminars in cell & developmental biology 114, 93-112, 2021 | 83 | 2021 |
| JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition AS McKenney, AN Lau, AVH Somasundara, B Spitzer, AM Intlekofer, ... The Journal of clinical investigation 128 (2), 789-804, 2018 | 79 | 2018 |
| Targeting the CALR interactome in myeloproliferative neoplasms E Pronier, P Cifani, TR Merlinsky, KB Berman, AVH Somasundara, ... JCI insight 3 (22), 2018 | 58 | 2018 |
| Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis E Pronier, RL Bowman, J Ahn, J Glass, C Kandoth, TR Merlinsky, ... Blood, The Journal of the American Society of Hematology 132 (12), 1265-1278, 2018 | 48 | 2018 |
| Synergistic therapeutic efficacy of combined JAK1/2, Pan-PIM, and CDK4/6 inhibition in myeloproliferative neoplasms RK Rampal, PO Maria, HSA Varshini, RL Levine, A Cao Blood 128 (22), 634, 2016 | 22 | 2016 |
| Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms GS Hobbs, AVH Somasundara, M Kleppe, R Litvin, M Arcila, J Ahn, ... Haematologica 103 (1), e5, 2018 | 19 | 2018 |
| Parity-induced changes to mammary epithelial cells control NKT cell expansion and mammary oncogenesis AVH Somasundara, MA Moss, MJ Feigman, C Chen, SL Cyrill, ... Cell reports 37 (10), 2021 | 16 | 2021 |
| Therapeutic efficacy of combined JAK1/2, Pan-PIM, and CDK4/6 inhibition in myeloproliferative neoplasms RK Rampal, M Pinzon-Ortiz, AVH Somasundara, B Durham, R Koche, ... Clinical Cancer Research 27 (12), 3456-3468, 2021 | 14 | 2021 |
| Myocardial Infarction Exome Sequencing SA Khetarpal, KT Schjoldager, C Christoffersen, A Raghavan, ... S., Kirchgessner, TG, Wandall, HH, Hansen, L., Bennett, EP, Vakhrushev, SY …, 2016 | 13 | 2016 |
| Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms AJ Dunbar, RL Bowman, YC Park, K O'Connor, F Izzo, RM Myers, ... Cancer discovery 14 (5), 737-751, 2024 | 9 | 2024 |
| Host response during unresolved urinary tract infection alters female mammary tissue homeostasis through collagen deposition and TIMP1 S Henry, SM Lewis, SL Cyrill, MK Callaway, D Chatterjee, ... Nature Communications 15 (1), 3282, 2024 | | 2024 |
| Combination JAK1/2 and CDK8/19 inhibition demonstrates enhanced efficacy in myeloproliferative neoplasms Z Zaroogian, E Adamczyk, A Moszyńska, M Obacz, U Pakulska, B Durham, ... Cancer Research 84 (6_Supplement), 7225-7225, 2024 | | 2024 |
| P986: COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS Z Zaroogian, E Adamczyk, A Moszyńska, M Obacz, U Pakulska, B Durham, ... HemaSphere 7 (S3), e133428d, 2023 | | 2023 |
| Investigating the role of changes to the mammary gland immune microenvironment in pregnancy-induced oncoprotection AV Hanasoge Somasundara Cold Spring Harbor Laboratory, 2022 | | 2022 |
